Alnylam Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNY)

$122.88 +1.14 (+0.94 %)
(As of 02/19/2018 10:54 AM ET)
Previous Close$121.74
Today's Range$121.27 - $124.03
52-Week Range$45.00 - $147.63
Volume653,500 shs
Average Volume895,518 shs
Market Capitalization$12.27 billion
P/E Ratio-22.71
Dividend YieldN/A
Beta2.69

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Debt-to-Equity Ratio0.02%
Current Ratio12.23%
Quick Ratio12.23%

Price-To-Earnings

Trailing P/E Ratio-22.7134515463003
Forward P/E Ratio-18.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$89.91 million
Price / Sales136.49
Cash FlowN/A
Price / CashN/A
Book Value$17.96 per share
Price / Book6.84

Profitability

Trailing EPS($5.41)
Net Income$-490,870,000.00
Net Margins-545.95%
Return on Equity-41.08%
Return on Assets-33.16%

Miscellaneous

Employees514
Outstanding Shares99,870,000

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.38) by $0.10. The biopharmaceutical company earned $37.90 million during the quarter, compared to analysts' expectations of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. Alnylam Pharmaceuticals's revenue for the quarter was up 116.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When will Alnylam Pharmaceuticals make its next earnings announcement?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Alnylam Pharmaceuticals.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2018?

21 Wall Street analysts have issued 12-month price objectives for Alnylam Pharmaceuticals' stock. Their forecasts range from $56.00 to $200.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $135.05 in the next year. View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. Chardan Capital analysts commented, "We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations." (1/19/2018)
  • 2. FBR & Co analysts commented, "We are initiating coverage of Alnylam Pharmaceuticals, Inc. (ALNY), making it our Alpha Generator pick, with a Buy rating and a 12-month price target of $150 per share, due to our utmost conviction that Alnylam represents a foundational biopharma investment, led by the firm’s hereditary transthyretin amyloidosis (hATTR) franchise." (10/30/2017)
  • 3. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)
  • 4. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:

  • Michael W. Bonney, Independent Chairman of the Board (Age 58)
  • Barry E. Greene, President (Age 53)
  • John M. Maraganore Ph.D., Chief Executive Officer, Director (Age 54)
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer (Age 39)
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President (Age 54)
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development (Age 54)
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary (Age 62)
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada (Age 57)
  • Peter F. Smith Ph.D., Senior Vice President - Early Development (Age 59)

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), FMR LLC (15.00%), BlackRock Inc. (7.24%), UBS Asset Management Americas Inc. (1.42%), Perceptive Advisors LLC (1.33%) and Gilder Gagnon Howe & Co. LLC (1.24%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, David-Alexandre C Gros, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, First Trust Advisors LP, Perceptive Advisors LLC, Slate Path Capital LP, Rockefeller Financial Services Inc., Teachers Retirement System of The State of Kentucky, Frontier Capital Management Co. LLC and 683 Capital Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating and Michael Mason. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Swiss National Bank, Two Sigma Investments LP, TIAA CREF Investment Management LLC, Alexandria Capital LLC, Tocqueville Asset Management L.P., Bridger Management LLC and Two Sigma Advisers LP. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $122.88.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $12.27 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. Alnylam Pharmaceuticals employs 514 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (ALNY)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  720 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  994
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.622.622.572.61
Ratings Breakdown: 3 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
3 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $135.05$128.65$129.40$83.44
Price Target Upside: 10.93% upside3.76% upside2.39% upside6.68% upside

Alnylam Pharmaceuticals (NASDAQ:ALNY) Consensus Price Target History

Price Target History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018B. RileyLower Price TargetBuy -> Buy$205.00 -> $200.00MediumView Rating Details
2/9/2018Credit Suisse GroupSet Price TargetBuy$151.00LowView Rating Details
2/9/2018Jefferies GroupSet Price TargetBuy$156.00LowView Rating Details
2/9/2018NomuraBoost Price TargetSell$86.00LowView Rating Details
2/9/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$165.00 -> $160.00MediumView Rating Details
2/9/2018Morgan StanleyLower Price TargetEqual Weight -> Equal Weight$128.00 -> $118.00MediumView Rating Details
1/25/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$132.00 -> $135.00LowView Rating Details
1/19/2018Chardan CapitalReiterated RatingBuyLowView Rating Details
1/7/2018Piper Jaffray CompaniesReiterated RatingBuy$182.00MediumView Rating Details
12/15/2017Goldman Sachs GroupUpgradeBuy -> Conviction-BuyHighView Rating Details
11/9/2017CowenReiterated RatingBuy$151.00N/AView Rating Details
11/9/2017JPMorgan Chase & Co.UpgradeNeutral -> OverweightN/AView Rating Details
11/8/2017BarclaysBoost Price TargetOverweight$127.00 -> $158.00N/AView Rating Details
11/3/2017Needham & Company LLCReiterated RatingBuy -> Buy$125.00 -> $152.00N/AView Rating Details
10/30/2017FBR & CoInitiated CoverageBuy -> Buy$150.00N/AView Rating Details
9/21/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$90.00 -> $146.00LowView Rating Details
9/21/2017Sanford C. BernsteinReiterated RatingOutperform -> Buy$94.00 -> $135.00LowView Rating Details
9/20/2017Stifel NicolausReiterated RatingHold$56.00 -> $83.00LowView Rating Details
9/20/2017JMP SecuritiesBoost Price TargetOutperform$101.00 -> $128.00LowView Rating Details
9/15/2017InstinetInitiated CoverageReduce -> Reduce$56.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings History and Estimates Chart

Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ ALNY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018($1.34)N/AView Earnings Details
2/8/2018Q4 2017($1.38)($1.48)$19.31 million$37.90 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.23)($1.34)$28.15 million$17.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.22)($1.34)$23.86 million$15.93 millionViewListenView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.39)($0.23)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.30)($0.35)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.30)($0.29)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.30)($0.19)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.24)($0.22)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.29)($0.55)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.24)($0.19)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.15)($0.23)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.21)($0.07)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.09)($0.31)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.14)($0.03)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.22)$0.04ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings Estimates

2018 EPS Consensus Estimate: ($4.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.44)($1.25)($1.35)
Q2 20183($1.64)($1.46)($1.54)
Q3 20183($1.56)($0.69)($1.13)
Q4 20183($1.46)($0.14)($0.93)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 88.61%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2018Michael MasonVPSell36,745$131.59$4,835,274.556,352View SEC Filing  
12/20/2017Laurie KeatingSVPSell6,249$121.20$757,378.8017,749View SEC Filing  
12/1/2017Laurie KeatingSVPSell30,000$135.89$4,076,700.0041,500View SEC Filing  
11/22/2017John MaraganoreCEOSell73,415$130.90$9,610,023.50223,125View SEC Filing  
11/15/2017John MaraganoreCEOSell74,000$126.86$9,387,640.00223,710View SEC Filing  
11/2/2017Dennis A AusielloDirectorSell20,000$130.00$2,600,000.0020,000View SEC Filing  
10/30/2017Akshay VaishnawEVPSell33,666$121.46$4,089,072.3645,201View SEC Filing  
10/2/2017Barry E GreenePresidentSell85,316$125.00$10,664,500.00View SEC Filing  
9/20/2017Barry E GreenePresidentSell76,815$100.00$7,681,500.00165,399View SEC Filing  
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.0011,500View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.0021,297View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.005,625View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.0043,047View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00155,795View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00155,795View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.3534,915View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19148,465View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46148,465View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00100View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56133,389View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00140,795View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43133,389View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20133,389View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.003,905View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64106,320View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.003,905View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.6012,588View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.0018,617View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alnylam Pharmaceuticals (NASDAQ ALNY) News Headlines

Source:
DateHeadline
Alnylam Pharmaceuticals (ALNY) Given New $200.00 Price Target at B. RileyAlnylam Pharmaceuticals (ALNY) Given New $200.00 Price Target at B. Riley
www.americanbankingnews.com - February 16 at 9:52 AM
Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2017Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 15 at 5:01 PM
Alnylam Pharmaceuticals (ALNY) Presents At BIO CEO & Investor Conference - SlideshowAlnylam Pharmaceuticals (ALNY) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 4:02 PM
Alnylam Pharmaceuticals (ALNY) Price Target Cut to $118.00 by Analysts at Morgan StanleyAlnylam Pharmaceuticals (ALNY) Price Target Cut to $118.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - February 10 at 1:56 PM
Alnylam Pharmaceuticals (ALNY) Given a $151.00 Price Target by Credit Suisse Group AnalystsAlnylam Pharmaceuticals (ALNY) Given a $151.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - February 10 at 11:40 AM
Alnylam Pharmaceuticals (ALNY) Rating Reiterated by Jefferies GroupAlnylam Pharmaceuticals (ALNY) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - February 10 at 12:18 AM
Alnylam Pharmaceuticals (ALNY) Price Target Raised to $86.00Alnylam Pharmaceuticals (ALNY) Price Target Raised to $86.00
www.americanbankingnews.com - February 9 at 10:36 PM
BMO Capital Markets Trims Alnylam Pharmaceuticals (ALNY) Target Price to $160.00BMO Capital Markets Trims Alnylam Pharmaceuticals (ALNY) Target Price to $160.00
www.americanbankingnews.com - February 9 at 8:58 PM
Alnylam Pharma loss widens as costs riseAlnylam Pharma loss widens as costs rise
www.marketwatch.com - February 8 at 4:00 PM
Alnylam reports 4Q lossAlnylam reports 4Q loss
finance.yahoo.com - February 8 at 4:00 PM
Alnylam Pharmaceuticals (ALNY) Issues  Earnings ResultsAlnylam Pharmaceuticals (ALNY) Issues Earnings Results
www.americanbankingnews.com - February 8 at 11:37 AM
Alnylam Pharmaceuticals, Inc to Host Earnings CallAlnylam Pharmaceuticals, Inc to Host Earnings Call
finance.yahoo.com - February 8 at 8:31 AM
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period ActivityAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
finance.yahoo.com - February 8 at 8:31 AM
Affimed, Alnylam Are End Of The Week Movers In BiotechAffimed, Alnylam Are End Of The Week Movers In Biotech
finance.yahoo.com - February 5 at 3:59 PM
Alnylam to Webcast Presentations at Upcoming February Investor ConferencesAlnylam to Webcast Presentations at Upcoming February Investor Conferences
finance.yahoo.com - February 5 at 9:33 AM
Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $26.90 MillionZacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $26.90 Million
www.americanbankingnews.com - February 4 at 4:38 AM
 Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Earnings of -$1.38 Per Share Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Earnings of -$1.38 Per Share
www.americanbankingnews.com - February 2 at 2:22 PM
Alnylams (ALNY) RNAi Candidates NDA Gets Priority ReviewAlnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
www.zacks.com - February 2 at 9:36 AM
Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) AmyloidosisAlnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
finance.yahoo.com - February 2 at 9:36 AM
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial ResultsAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 1 at 9:39 AM
Sanofi On A Buyout Spree This Month: Announces Ablynx Acquisition For $4.8 BillionSanofi On A Buyout Spree This Month: Announces Ablynx Acquisition For $4.8 Billion
www.benzinga.com - January 31 at 10:00 AM
Alnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from AnalystsAlnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 30 at 5:36 PM
Alnylam Pharmaceuticals (ALNY) to Release Earnings on TuesdayAlnylam Pharmaceuticals (ALNY) to Release Earnings on Tuesday
www.americanbankingnews.com - January 30 at 2:56 AM
STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific AdvisorSTORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor
finance.yahoo.com - January 29 at 4:02 PM
Leerink Swann Weighs in on Alnylam Pharmaceuticals, Inc.s FY2017 Earnings (ALNY)Leerink Swann Weighs in on Alnylam Pharmaceuticals, Inc.'s FY2017 Earnings (ALNY)
www.americanbankingnews.com - January 29 at 1:26 AM
Alnylam Pharmaceuticals (ALNY) Given New $135.00 Price Target at Leerink SwannAlnylam Pharmaceuticals (ALNY) Given New $135.00 Price Target at Leerink Swann
www.americanbankingnews.com - January 27 at 6:06 PM
Alnylam Pharma (ALNY) Announces EMA Acceptance of MAA for Patisiran for hATTR AmyloidosisAlnylam Pharma (ALNY) Announces EMA Acceptance of MAA for Patisiran for hATTR Amyloidosis
www.streetinsider.com - January 26 at 9:44 AM
Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) AmyloidosisAlnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
finance.yahoo.com - January 25 at 4:02 PM
Why 2017 Was a Year to Remember for Ionis Pharmaceuticals, Inc.Why 2017 Was a Year to Remember for Ionis Pharmaceuticals, Inc.
www.fool.com - January 22 at 12:34 PM
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock DipsSanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips
www.nasdaq.com - January 22 at 12:34 PM
Alnylam Pharmaceuticals (ALNY) Stock Rating Reaffirmed by Chardan CapitalAlnylam Pharmaceuticals (ALNY) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - January 20 at 4:52 PM
Alnylam Pharmaceuticals (ALNY) Stock Rating Reaffirmed by B. RileyAlnylam Pharmaceuticals (ALNY) Stock Rating Reaffirmed by B. Riley
www.americanbankingnews.com - January 19 at 8:04 PM
Zacks: Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $26.90 MillionZacks: Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $26.90 Million
www.americanbankingnews.com - January 18 at 9:40 AM
 Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Earnings of -$1.40 Per Share Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Earnings of -$1.40 Per Share
www.americanbankingnews.com - January 16 at 11:42 AM
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
finance.yahoo.com - January 14 at 9:10 AM
Alnylam CEO responds to Trump: ‘I’m proud to be a ‘s***holer!’’Alnylam CEO responds to Trump: ‘I’m proud to be a ‘s***holer!’’
finance.yahoo.com - January 12 at 3:25 PM
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017 - Motley FoolThis Is Why Alnylam Pharmaceuticals Soared 249% in 2017 - Motley Fool
www.fool.com - January 12 at 8:52 AM
Brokers Offer Predictions for Alnylam Pharmaceuticals, Inc.s FY2017 Earnings (ALNY)Brokers Offer Predictions for Alnylam Pharmaceuticals, Inc.'s FY2017 Earnings (ALNY)
www.americanbankingnews.com - January 10 at 8:02 AM
FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. Raised by Jefferies Group (ALNY)FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. Raised by Jefferies Group (ALNY)
www.americanbankingnews.com - January 10 at 8:00 AM
Alnylam Pharma (ALNY) Releases Corporate Goals for 2018Alnylam Pharma (ALNY) Releases Corporate Goals for 2018
www.streetinsider.com - January 9 at 9:46 AM
Alnylam Pharmaceuticals, Inc. (ALNY) VP Sells $4,835,274.55 in StockAlnylam Pharmaceuticals, Inc. (ALNY) VP Sells $4,835,274.55 in Stock
www.americanbankingnews.com - January 8 at 6:50 PM
Alnylam Pharma (ALNY) Releases Corporate Goals for 2018 - StreetInsider.comAlnylam Pharma (ALNY) Releases Corporate Goals for 2018 - StreetInsider.com
www.streetinsider.com - January 8 at 3:31 PM
UPDATE 1-Regeneron forms consortium to accelerate gene sequencing project - ReutersUPDATE 1-Regeneron forms consortium to accelerate gene sequencing project - Reuters
www.reuters.com - January 8 at 3:31 PM
Alnylam Pharmaceuticals (ALNY) Given "Buy" Rating at Piper Jaffray CompaniesAlnylam Pharmaceuticals (ALNY) Given "Buy" Rating at Piper Jaffray Companies
www.americanbankingnews.com - January 8 at 1:38 PM
Sanofi to market new hemophilia drug in deal with AlnylamSanofi to market new hemophilia drug in deal with Alnylam
finance.yahoo.com - January 8 at 11:05 AM
Sanofi: Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease allianceSanofi: Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
www.finanznachrichten.de - January 7 at 3:40 PM
Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease AllianceAlnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
finance.yahoo.com - January 7 at 3:40 PM
Alnylam Announces 2018 Corporate GoalsAlnylam Announces 2018 Corporate Goals
finance.yahoo.com - January 7 at 3:40 PM
Financial Contrast: Alnylam Pharmaceuticals (ALNY) and Its CompetitorsFinancial Contrast: Alnylam Pharmaceuticals (ALNY) and Its Competitors
www.americanbankingnews.com - January 7 at 3:11 AM
Alnylam Expands Alnylam Act™ Program to Include No-Charge ... - Business Wire (press release)Alnylam Expands Alnylam Act™ Program to Include No-Charge ... - Business Wire (press release)
www.businesswire.com - January 6 at 3:27 PM

SEC Filings

Alnylam Pharmaceuticals (NASDAQ:ALNY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alnylam Pharmaceuticals (NASDAQ:ALNY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alnylam Pharmaceuticals (NASDAQ ALNY) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.